News
Eli Lilly stock falls after new data on its weight-loss drug Orforglipron, ahead of scheduled second-quarter earnings.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results